Erythropoietin in stroke: quo vadis (Q37731533)

22 August 2017

1 reference

title

Erythropoietin in stroke: quo vadis (English)

1 reference

22 August 2017

1 reference

Murat Digicaylioglu

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

937-949

1 reference

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Prioritizing interventions to improve rates of thrombolysis for ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

The non-haematopoietic biological effects of erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Survival and proliferative roles of erythropoietin beyond the erythroid lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Functional and immunochemical characterisation of different antibodies against the erythropoietin receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin and normal brain development: receptor expression determines multi-tissue response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Cellular and molecular mechanisms of neural repair after stroke: making waves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Poststroke neurogenesis: emerging principles of migration and localization of immature neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

In vivo evidence that erythropoietin protects neurons from ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Angiogenesis and plasticity: role of erythropoietin in vascular systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Astroglial cytoprotection by erythropoietin pre-conditioning: implications for ischemic and degenerative CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Neuroprotection by erythropoietin administration after experimental traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin prevents blood brain barrier damage induced by focal cerebral ischemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Effects of erythropoietin on blood-brain barrier disruption in focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Recombinant human erythropoietin in the treatment of acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

The neurotoxicity of tissue plasminogen activator?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Current status of neuroprotection for cerebral ischemia: synoptic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

1,026 experimental treatments in acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Recommendations for clinical trial evaluation of acute stroke therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Update of the stroke therapy academic industry roundtable preclinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

The blood-brain barrier in health and chronic neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Drug targeting to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Blood-brain barrier delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Changes in blood-brain barrier permeability to large and small molecules following traumatic brain injury in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

A potential role for erythropoietin in focal permanent cerebral ischemia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Neuroprotective effect of erythropoietin, and role of metallothionein-1 and -2, in permanent focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Drug targeting to the brain using avidin-biotin technology in the mouse; (blood-brain barrier, monoclonal antibody, transferrin receptor, Alzheimer's disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Biotin transport through the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Biotin uptake and transport across bovine brain microvessel endothelial cell monolayers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Cerebral ischemia-reperfusion injury in rats--a 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin protects CA1 neurons against global cerebral ischemia in rat: potential signaling mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Delivery of interferon-beta to the monkey nervous system following intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal administration of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, enhances total uptake and bioavailability in Swiss Webster mice when compared to intraperitoneal, subcutaneous, and intramuscular delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Direct nose-to-brain transfer of a growth hormone releasing neuropeptide, hexarelin after intranasal administration to rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery to the central nervous system: mechanisms and experimental considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin as an angiogenic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Intranasal delivery of cells to the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Is nose-to-brain transport of drugs in man a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Can nasal drug delivery bypass the blood-brain barrier?: questioning the direct transport theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Combination of deferoxamine and erythropoietin: therapy for hypoxia-ischemia-induced brain injury in the neonatal rat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Nanosystem drug targeting: Facing up to complex realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

Drug delivery to damaged brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

From nose to brain: understanding transport capacity and transport rate of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.481435

10.1517/14712598.2010.481435

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference